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Abstract
Introduction: The objective of the present study was to analyse secular trends in antibiotic consumption and 
resistance data from a network of 53 intensive care units (ICUs).
Methods: The study involved prospective unit and laboratory-based surveillance in 53 German ICUs from 2001 
through 2008. Data were calculated on the basis of proportions of nonduplicate resistant isolates, resistance densities 
(that is, the number of resistant isolates of a species per 1,000 patient-days) and an antimicrobial usage density (AD) 
expressed as daily defined doses (DDD) and normalised per 1,000 patient-days.
Results: Total mean antibiotic use remained stable over time and amounted to 1,172 DDD/1,000 patient-days (range 
531 to 2,471). Carbapenem use almost doubled to an AD of 151 in 2008. Significant increases were also calculated for 
quinolone (AD of 163 in 2008) and third-generation and fourth-generation cephalosporin use (AD of 117 in 2008). 
Aminoglycoside consumption decreased substantially (AD of 86 in 2001 and 24 in 2008). Resistance proportions were 
as follows in 2001 and 2008, respectively: methicillin-resistant Staphylococcus aureus (MRSA) 26% and 20% (P = 0.006; 
trend test showed a significant decrease), vancomycin-resistant enterococcus (VRE) faecium 2.3% and 8.2% (P = 0.008), 
third-generation cephalosporin (3GC)-resistant Escherichia. coli 1.2% and 19.7% (P < 0.001), 3GC-resistant Klebsiella 
pneumoniae 3.8% and 25.5% (P < 0.001), imipenem-resistant Acinetobacter baumannii 1.1% and 4.5% (P = 0.002), and 
imipenem-resistant K. pneumoniae 0.4% and 1.1%. The resistance densities did not change for MRSA but increased 
significantly for VRE faecium and 3GC-resistant E. coli and K. pneumoniae. In 2008, the resistance density for MRSA was 
3.73, 0.48 for VRE, 1.39 for 3GC-resistant E. coli and 0.82 for K. pneumoniae.
Conclusions: Although total antibiotic use did not change over time in German ICUs, carbapenem use doubled. This is 
probably due to the rise in 3GC-resistant E. coli and K. pneumoniae. Increased carbapenem consumption was associated 
with carbapenem-resistant K. pneumoniae carbapenemase-producing bacteria and imipenem-resistant A. baumannii.
Introduction
I n  r e c e n t  y e a r s ,  a n  i n c r e a s e d  e f f o r t  h a s  b e e n  d i r e c t e d
towards controlling antibiotic use and raising public
awareness of the need for prudent use of antibiotics [1].
There are two main reasons for this. The first is ecologi-
cal, in that antibiotics induce and select for bacterial
resistance [2]. Resistance is meanwhile considered a
global threat, and pathogens susceptible to antibiotics are
considered a common good [3]. Antimicrobial drug effec-
tiveness cannot be taken for granted and antimicrobials
are increasingly attaining the status of nonrenewable
resources. The second reason is economic, in that antibi-
otics account for a large portion of a hospital's pharmacy
budget, and in the face of restricted financial resources
are therefore a main target for cost savings [4]. Over the
past decade, many surveillance efforts have drawn atten-
tion to this phenomenon [5-8].
The Surveillance System of Antibiotic Use and Bacte-
rial Resistance in Intensive Care Units (SARI) is an ongo-
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ing project, launched in 2000 and initially funded by the
German Government, that collects data from its network
of intensive care units (ICUs) [9-12]. SARI focuses on the
critically ill because antimicrobial use in ICUs is among
the highest in the hospital setting and consumption often
runs in parallel to the pattern seen for resistance.
The goal of the present study is to give an overview of
changes in antibiotic consumption and resistance in a
network of ICUs over a period of 8 years (2001 through
2008).
Materials and methods
SARI started in February 2000. Following a pilot phase,
we first analysed data at the beginning of 2001. Data from
53 SARI ICUs were included in the analysis presented
here: 21 of the 53 ICUs were interdisciplinary, 18 were
surgical (of which four were neurosurgical) and 14 were
medical. Most ICUs were located in hospitals affiliated
with a university hospital (n = 30) or in university hospi-
tals (n = 19). The median of hospital size was 790 beds
(interquartile range 463 to 1,119 beds), and the median
number of ICU beds was 12 (interquartile range 10 to 18
beds).
Data are fed back to the participants every 6 months.
From 2001 through 2008, the numbers of ICUs reporting
data to the project were 36, 35, 38, 40, 44, 46, 45 and 45,
respectively. Forty-seven per cent of the ICUs sent data
from all 8 years.
Data collection
Monthly data on antimicrobial use were obtained from
the computerised pharmacy databases. Consumption -
that is, the antimicrobial usage density (AD) - was
expressed as daily defined doses (DDD) and was norma-
lised per 1,000 patient-days. The DDD are the standard
adult daily dose of an antimicrobial agent for a 1-day
treatment defined by the World Health Organisation
(WHO ATC/DDD Index 2008) [13].
The ICUs indicated the number of isolates tested per
month belonging to the following 13 sentinel bacterial
species:  Staphylococcus aureus, coagulase-negative
staphylococci,  Enterococcus faecalis,  Enterococcus fae-
cium,  Pseudomonas aeruginosa,  Enterobacter cloacae,
Citrobacter spp., Serratia marcescens, Acinetobacter bau-
mannii,  Stenotrophomonas maltophilia, Streptococcus
pneumoniae, Escherichia coli and Klebsiella pneumoniae.
The susceptibility data were collected from the microbi-
ology laboratory for these 13 pathogens regardless of
whether they were associated with hospital-acquired or
community-acquired infection or colonisation, or
whether they were from clinical or surveillance cultures.
Pathogens were specified as resistant by the clinical labo-
ratory using interpretive criteria recommended by the
German Industrial standard or CLSI. Copy strains -
defined as an isolate of the same species showing the
same susceptibility pattern throughout a period of 1
month in the same patient, no matter what the site of iso-
lation - were excluded. Thirty-seven per cent of the SARI
ICUs - 13 out of 35 SARI ICUs responded to a question-
naire on methicillin-resistant S. aureus (MRSA) manage-
ment in 2008 - screened all patients for MRSA at
admission. Questions on extended-spectrum β-lactamase
(ESBL) screening were not included.
All data were anonymous and were collected in accor-
dance with the German recommendations of good epide-
miological praxis with respect to data protection [14]. As
a federal law, the German Protection against Infection
Act (Infektionsschutzgesetz §23) regulates the prevention
and management of infectious disease in humans. All
hospitals are obliged to collect and analyse continuously
nosocomial infections and resistant pathogens [15].
These routine data were reported to the National Refer-
ence Centre of the Surveillance of Nosocomial Infections.
Ethical approval and informed consent were thus not
required.
Statistical analysis
The proportion of resistant isolates was calculated by
dividing the number of resistant isolates by the total
number of the isolates of the same species tested against
the corresponding antibiotic multiplied by 100. The inci-
dence density of resistant isolates (RD) was defined as
being the number of resistant isolates per 1,000 patient-
days. Differences in consumption and resistance by type
of ICU were tested using the Kruskal-Wallis test. From
2001 through 2008, trends in resistance were analysed by
regression analysis using aggregated 3-monthly data (24
time points) and trends in antibiotic use were analysed
using monthly data (96 time points). We tested whether
the linear regression coefficient was significantly different
from zero.
The significance level was P < 0.05 and all analyses were
performed using EpiInfo 6.04 and SAS 9.2 (SAS Institute
Inc., Cary, NC, USA).
Results
From 2001 through 2008, a total of 53 ICUs from 30 hos-
pitals reported data to SARI covering 1,335,855 patient-
days. The mean length of stay was 4.2 days in 2001 and
4.0 days in 2008. The rate of ventilated patients ranged
between 45 and 49% over the 8-year period. Altogether,
121,548 pathogens (53% of them Gram-positive) were
isolated with a mean number of 91 pathogens per 1,000
patient-days.
Pooled mean antibiotic use over the 8-year period was
1,172 DDD/1,000 patient-days; that is, each patient on
average received 1.2 DDD. Antibiotic consumption
ranged from 531 to 2,471 DDD/1,000 patient-daysMeyer et al. Critical Care 2010, 14:R113
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(median 1,213 DDD/1,000 patient-days). The proportions
of β-lactamase-sensitive penicillins, of penicillins with
extended spectrum, of β-lactamase-resistant penicillins
and of penicillins with β-lactamase inhibitor among the
whole class of penicillins were 7.4%, 32.8%, 8.9%, and
51.9%, respectively (2001 to 2008). Figure 1 shows the
heterogeneity of total antibiotic consumption and distri-
bution over antibiotic classes in individual ICUs.
Total mean antibiotic use (without sulbactam)
remained stable over time (P = 0.707). The AD was 1,180
DDD/1,000 patient-days in 2001 and was 1,167 DDD/
1,000 patient-days in 2008. There was no difference either
in total antibiotic use or in the trend over time by type of
ICU.
Within the antibiotic classes, carbapenem use almost
doubled to an AD of 151 in 2008 (Figure 2). Carbapenem
use and third-generation cephalosporin (3GC) resistance
correlated significantly (P = 0.036; correlation coefficient
= 0.291). Significant increases were also calculated for
quinolones and for third-generation and fourth-genera-
tion cephalosporin use. Consumption of the whole class
of cephalosporins and penicillins, however, decreased
significantly. Aminoglycosides showed the biggest
decrease over time (P < 0.001). Macrolide use was signifi-
cantly higher in medical ICUs, whereas second-genera-
tion cephalosporin consumption was significantly lower
in medical ICUs than in surgical or interdisciplinary
ICUs.
The most striking result was the continuous increase of
3GC-resistant E. coli (%), which equated to an almost 10-
fold increase within just 8 years. Vancomycin-resistant
Enterococcus  (VRE)  faecium  quadrupled between 2006
and 2008 (Table 1). In contrast, the proportion of MRSA
even decreased and the resistance proportions of imi-
penem-resistant or ciprofloxacin-resistant P. aeruginosa
revealed no trend at all.
Resistance differed by type of ICU: ciprofloxacin resis-
tance in P. aeruginosa was significantly higher in medical
and interdisciplinary ICUs than in surgical ICUs. In con-
trast, vancomycin resistance in E. faecium was signifi-
cantly higher in medical ICUs.
It is also possible to demonstrate the different dynamics
of resistant pathogens if the RD is used as a parameter for
the burden of resistance (Figure 3). Although at 3.73
MRSA/1,000 patient-days MRSA still presented the high-
est burden of resistant pathogens in 2008, the burden of
3GC-resistant E. coli was a remarkable 1.39 ESBL iso-
lates/1,000 patient-days. This means that in 2008 the RD
of 3GC-resistant E. coli I was equivalent to more than
one-third of the overall RD of MRSA. The burden of imi-
Figure 1 Antibiotic consumption in 53 German intensive care units from 2001 to 2008. DDD, defined daily doses; pd, patient-days.Meyer et al. Critical Care 2010, 14:R113
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penem-resistant K. pneumoniae was still low at 0.05 per
1,000 patient-days in 2008, which corresponds to seven
isolates from two separate ICUs.
Figure 4a, b shows the pooled mean and the median of
carbapenem use and 3GC resistance in E. coli. Resistance
started to increase in parallel in 2006, indicating that the
increase was not only based on some outlier ICUs but
affected almost all ICUs. Indeed, since 2006 just four
ICUs have not been confronted with 3GC-resistant E.
coli. The resistance proportions of 3GC-resistant E. coli
in the other ICUs ranged from 2 to 24% and the RD from
0.1 to 4.6. The burden of 3GC-resistant E. coli even out-
numbered the burden of MRSA in seven ICUs.
Discussion
The three main findings of this study are: that total anti-
biotic consumption remained stable from 2001 through
2008 with a mean use of 1.2 DDD per patient per ICU-
day; that the burden of resistance increased dramatically
for 3GC-resistant E. coli and K. pneumoniae over 8 years,
but not for MRSA; and that our data demonstrate the
dangerous spiral of spread of resistance and antibiotic use
- the increase in 3GC resistance, which indicates a rise in
ESBL-producing bacteria, has been followed by a dou-
bling of carbapenem use that, in turn, might now be fol-
lowed by an increase in imipenem-resistant pathogens.
Antibiotic consumption varied widely by the factor of
five, which may partially be explained by differences in
patients and ICU characteristics, antibiotic policies or
physicians' level of education. Although quantitative data
must not be taken as qualitative parameters, the hetero-
geneity of antibiotic prescriptions might still indicate that
antimicrobial use can be improved. We were able to show
in three intervention studies that it was indeed possible to
sustainably reduce antibiotic consumption in SARI ICUs
by shortening the duration of treatment or revising anti-
biotic prophylaxis [16-18]. Generally, total median antibi-
otic use of 1,213 DDD/1,000 patient-days concurs with
data from 35 ICUs in eight European countries in 2005,
with a median of 1,254 DDD/1,000 patient-days (also
Figure 2 Change in antibiotic consumption in German intensive care units from 2001 to 2008. DDD, defined daily doses; pd, patient-days; 
1&2GC, first-generation and second-generation cephalosporins; 3&4GC, third-generation and fourth-generation cephalosporins. P value for the linear 
regression coefficient and trend (increase, +; decrease, -) in parentheses.Meyer et al. Critical Care 2010, 14:R113
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ranging widely from 348 to 4,992 DDD/1,000 patient-
days) [19]. In Swedish ICUs, antibiotic use increased sig-
nificantly from 1,245 DDD/1,000 patient-days in 1999 to
1,510 DDD/1,000 patient-days in 2003. In these ICUs,
antibiotic prescribing was empiric and adequate [20,21].
It can be assumed that antibiotic therapy is also widely
empiric in SARI ICUs because the mean ICU stay was
only 4.0 days. Empiric antibiotic therapy should be timely
and adequate; however, it will normally be broad in the
critically ill. The changed resistance situation - that is, the
increase in 3GC-resistant E. coli - was associated with a
doubling in carbapenem use.
The European Antimicrobial Resistance Surveillance
System described resistance against 3GC in E. coli as the
most dynamic expansion of multidrug-resistant patho-
gens in the entire region [22]. Although in 2008 just
under one-half of European countries (14 of 33) reported
their resistance levels against 3GC to be under 5%, since
2004 the proportion of 3GC resistance has increased in
19 European countries. In general, a large percentage of
ESBL-producing pathogens are now being imported into
hospitals and ICUs [23-25]. Known risk factors inside and
outside the hospital include use especially of broad-spec-
trum cephalosporins and quinolones, which, in some
ICUs at least, are the workhorses of antibiotic therapy
[26-28]. Use of these antibiotic classes might also contrib-
ute to the selection of ESBLs, to the persistence of pre-
dominant ESBL clones and to the probable dissemination
of conjugative plasmids among strains. Limiting adminis-
tration of these antibiotics to patients in which other
therapeutic alternatives according to evidence-based
guidelines are not possible is therefore part of many anti-
biotic stewardship programmes.
A shift toward greater carbapenem usage harbours the
risk of greater selection of carbapenem resistance and is
associated with permeability mutations in strains already
producing ESBLs or other potent β-lactamases [29]. This
is already happening, especially in Klebsiella. Current
reports indicate that K. pneumoniae carbapenemases
(KPC) are widespread in China, Israel, Greece, South
America, and the USA [29,30]. Fortunately, KPC-produc-
ing bacteria are still rare in Western Europe and North-
ern Europe. Although not yet broadly reflected in our
data - only two ICUs encountered imipenem-resistant K.
pneumoniae in 2008 - it is to be expected that such strains
will also be increasingly encountered in European ICUs,
because it has been shown that high level carbapenem-
resistant KPC-producing bacteria may be selected during
imipenem and meropenem therapy [31]. In contrast, the
increase in 3GC-resistant E. coli has now affected most
ICUs and is therefore unlikely to be a problem caused by
the selection pressure of antibiotic therapy in the individ-
ual ICU. If the import into the ICU and the burden of
multiresistant pathogens continues to increase, however,
Table 1: Pooled mean antimicrobial resistance of selected pathogens in German intensive care units (number of ICUs), 
2001 to 2008
Resistant pathogen (number tested 
against each antimicrobial)
2001
(n = 36)
2002
(n = 35)
2003
(n = 38)
2004
(n = 40)
2005
(n = 44)
2006
(n = 46)
2007
(n = 45)
2008
(n = 45)
P value*
Methicillin-resistant
Staphylococcus aureus (27,446)
26.0 22.4 20.9 19.5 22.6 22.2 20.6 19.5 0.006 (-)
Vancomycin-resistant
Enterococcus faecium (6,331)
2.3 1.2 1.2 5.4 5.4 2.2 3.6 8.2 0.008 (+)
3GC-resistant
Escherichia coli (18,425)
1.2 1.8 2.9 3.8 3.7 5.1 11.1 10.5 < 0.001 (+)
Ciprofloxacin-resistant
Escherichia coli (16,184)
8.3 11.9 14.1 16.5 18.2 16.4 20.9 24.2 < 0.001 (+)
3GC-resistant
Klebsiella pneumoniae (7,457)
3.8 12.2 5.9 6.5 6.5 6.5 10.4 15.1 < 0.007 (+)
Imipenem-resistant
Pseudomonas aeruginosa (10,468)
24.0 22.8 23.5 23.8 22.0 24.4 27.0 25.5 No trend
Ciprofloxacin-resistant
Pseudomonas aeruginosa (11,590)
19.7 18.4 15.6 19.5 17.4 19.3 17.0 16.0 No trend
Imipenem-resistant
Acinetobacter baumannii (2,014)
1.1 0.7 1.0 2.5 6.3 20.3 9.7 4.5 0.002 (+)
Imipenem-resistant
Klebsiella pneumoniae (5,732)
0.4 0.2 0.3 0.3 0.0 0.3 0.4 1.1 NA
ICU, intensive care unit; 3GC, third-generation cephalosporin; NA, not applicable because the assumptions of normal distribution are not fulfilled. 
*P value for the linear regression coefficient; +, increase; -, decrease.Meyer et al. Critical Care 2010, 14:R113
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adopting appropriate infection control strategies
becomes paramount to prevent the transmission to other
patients. Besides the basic set of infection control mea-
sures, early identification by screening and accommodat-
ing patients with multidrug-resistant pathogens in single
rooms or cohort isolation is recommended [32].
The spread and emergence of resistance is multifaceted;
it is not driven by antibiotic use alone, but is, among
other things, also influenced by clonal spread of strains,
by resistance mechanisms that might differ by species,
the human and environmental reservoir, and by infection
control strategies, including screening policies. We
hypothesise that these factors at least partly explain why
MRSA resistance did not increase over the study period
but VRE did, why imipenem-resistant K. pneumoniae
increased but imipenem-resistant P. aeruginosa did not,
or why ciprofloxacin-resistant E. coli increased yet cipro-
floxacin-resistant P. aeruginosa did not.
For instance, cumulative German prevalence data from
2007 show that the percentage of ciprofloxacin-resistant
E. coli was even higher in the outpatient setting than in
ICU patients (29.2% vs. 21.9%) [33]. This indicates that
quinolone-resistant strains of E. coli are imported to
ICUs through the massive selective pressure of quinolo-
nes prescribed in the outpatient setting in Germany; out-
patient antibiotic use accounts for 85% of total antibiotic
use [34]. Furthermore, use of quinolones in therapy and
prophylaxis, especially in commercial poultry farming,
contributes to the emergence of resistant organisms in
the human population, especially in pathogens having
their reservoir in the gut. In contrast, the natural reser-
voir of A. baumannii is unknown and A. baumannii is
rarely found on the human skin or in the environment.
Higgins and colleagues presented global data on carbap-
enem-resistant  A. baumannii suggesting that carbap-
enem resistance developed after or during the spread of
the clonal lineages [35]. They explained that clonal lin-
eages originated worldwide in at least eight distinct loci
and then spread to new locations, possibly through
patient transfer. If clonal spread is probably responsible
Figure 3 Change in burden of resistance of multidrug-resistant pathogens from 2001 to 2008. MRSA, methicillin-resistant Staphylococcus au-
reus; Imi R Aci, imipenem-resistant Acinetobacter baumannii; VRE, vancomycin-resistant Enterococcus faecium; 3GC R Kleb, third-generation cepha-
losporin-resistant Klebsiella pneumoniae; 3GC R Eco, third-generation cephalosporin-resistant Escherichia coli.Meyer et al. Critical Care 2010, 14:R113
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for the spread of carbapenem-resistant A. baumannii,
then  A. baumannii infections may indicate a serious
infection-control problem. Although there was a tempo-
ral association between increases in carbapenem use and
imipenem resistance in A. baumannii in our study, it does
not prove a causal relationship.
The present study has several limitations. Whereas the
ec o logica l s t udy des ign ca n lead t o t he  f orm a t io n o f  a
hypothesis, ultimately it does not prove a causative rela-
tionship - which a patient-based study design is able to
establish. Potential confounders such as antimicrobial
stewardship interventions (for example, the feedback of
the data to the ICUs is a type of intervention) or promo-
tion of hand hygiene could have influenced antibiotic use
and antimicrobial resistance in individual ICUs. The
number of ICUs participating in SARI increased from 36
to 53, with 47% of the ICUs reporting data over the 8-year
period. ICUs that joined recently might therefore have
had different antimicrobial usage patterns, as well as a
different antimicrobial resistance situation. Outbreaks
m i g h t  h a v e  i n f l u e n c e d  p o o l e d  m e a n  r e s i s t a n c e  d a t a .
World Health Organisation DDD do not always correctly
reflect the actual prescribed daily dose [36,37]. This
inconsistency does not invalidate the systematic
approach of the World Health Organisation, and there-
fore ICUs should use the DDD to make national and
international comparisons of their antibiotic use.
Conclusions
Disturbingly, ICUs have little in reserve to control multi-
drug resistance among Gram-negative bacteria [38]. We
c o n s i d e r  f i v e  p o i n t s  t o  b e  o f  p a r a m o u n t  i m p o r t a n c e .
Firstly, ICUs must ensure proper detection in their labo-
ratories of extended-spectrum β-lactamases among KPC-
producing Enterobacteriaceae clinical isolates [39]. Sec-
ondly, treatment options for infections with multiresis-
tant Gram-negative bacteria and KPC-producing
organisms are limited. Besides tigecycline, therefore, old
antibiotics like aminoglycosides, fosfomycin, colistin and
rifampicin will have to be re-employed. Thirdly, treat-
ment duration should be as short as is clinically feasible
to reduce selection pressure [40]. Fourthly, screening on
admission, as already established for MRSA, might be
considered to address the increasing import of resistant
pathogens into the ICU and to minimise the risk of trans-
mission [24]. Finally, infection control - especially hand
hygiene, the purpose of which is to prevent person-to-
person spread - is elementary and crucial.
Key messages
• The burden of resistance increased dramatically for 
3GC-resistant E. coli and K. pneumoniae, which indi-
cates a rise in ESBL-producing bacteria.
• This increase has been followed by a doubling of 
carbapenem use from 2001 through 2008.
• Greater carbapenem use harbours the risk of greater 
selection of carbapenem resistance and is associated 
with permeability mutations in strains already pro-
ducing ESBLs or KPCs.
• Because treatment options for infections with multi-
resistant Gram-negative bacteria and KPC-producing 
organisms are limited, besides tigecycline, old antibi-
otics such as aminoglycosides, fosfomycin, and colis-
Figure 4 Third-generation cephalosporin-resistant Escherichia coli and carbapenem use from 2001 to 2008. (a) Percentage of third-genera-
tion cephalosporin-resistant (3GC) Escherichia coli. The pooled mean (solid line) and the median (dotted line) run almost parallel to one another. The 
sharp increase in 3CG-resistant E. coli starts in 2006 and affects almost all intensive care units (ICUs). The interquartile range (shaded area) shows that 
50% of all ICUs had resistance proportions between 5 and 15% in 2008. (b) Carbapenem use. The pooled mean (solid line) and the median (dotted 
line) run almost parallel to one another. In most ICUs the increase in carbapenem use also starts in 2006. The interquartile range (shaded area) shows 
that carbapenem use in 50% of all ICUs ranged between 70 and 190 daily defined doses (DDD)/1,000 patient-days (pd) in 2008.
(b) (a)Meyer et al. Critical Care 2010, 14:R113
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tin with or without rifampicin will have to be re-
employed.
• Adopting appropriate infection control strategies 
becomes paramount to prevent transmission to other 
patients.
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